J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ORIC stock, giving a Buy rating on December 5.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anupam Rama has given his Buy rating due to a combination of factors that highlight the potential of Oric Pharmaceuticals. The recent data presented at ESMO Asia 2025 for enozertinib, an EGFR/HER2 inhibitor, demonstrated significant efficacy and safety in treating various EGFR/HER2-mutated NSCLC populations. The drug exceeded Oric’s internal benchmarks for objective response rates and showed strong central nervous system activity, even in patients with active brain metastases, while maintaining a favorable safety profile with minimal off-target toxicities.
Furthermore, the promising results from the Phase 1b study suggest that enozertinib could be a valuable asset for Oric Pharmaceuticals, with potential for further development in front-line settings. The stock is seen as undervalued, particularly with the ongoing focus on ORIC-944, and the positive outcomes from enozertinib provide an additional lever for value creation. Rama’s Buy rating reflects confidence in the company’s strategic direction and the potential for significant returns as the drug progresses through clinical trials.
According to TipRanks, Rama is a 5-star analyst with an average return of 16.7% and a 52.74% success rate. Rama covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Oric Pharmaceuticals, and BridgeBio Pharma.
In another report released on December 5, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.